Axiom’s eClinical suite Fusion will deliver tools required for electronic data collection and electronic patient reported outcomes. Credit: University of Oxford.

Unified eClinical solutions provider Axiom Real-Time Metrics has announced its partnership with the University of Oxford for its clinical trial focused on the preventative treatments of Covid-19.

Named COPCOV, the trial is led by the University of Oxford-supported Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is designed to recruit 40,000 frontline healthcare workers and staff in Europe, Africa, Asia, and South America.

The study began in April this year. It will run for one year and is currently the ‘largest interventional trial’ being conducted at a global level.

Axiom’s eClinical suite Fusion will deliver tools required for electronic data collection and electronic patient-reported outcomes.

Axiom founder and CEO Andrew Schachter said: “We are honoured that the University of Oxford and its collaborators have placed their trust in Axiom with respect to the criticality of the of real-time capture of clinical daily patient reported outcomes to this study and the management of its trial data.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Over the past 20 years, Axiom has supported trials of global importance, and this study is no exception. Indeed, it is unprecedented in many aspects. Playing our part to enable this study is a point of pride for the entire Axiom global team.”

Fusion will also deliver randomisation and reporting functions for the study.

Mahidol Oxford Research Unit data management head Naomi Waithira said: “It’s been a pleasure working with the Axiom team as we rapidly configured this study in just a few weeks. I greatly appreciate their contributions to our research.”

In March this year, Researchers at the University of Oxford in the UK commenced enrolment of healthy volunteers for a clinical trial of the Covid-19 vaccine candidate ChAdOx1 nCoV-19.